30. Use of Aperio Imagescope to Quantitate the Expression of LOXL2 in Normal and Cancerous Pancreata

Savannha Cookenour Indiana University-Purdue University Indianapolis, Max Jacobsen Indiana University-Purdue University Indianapolis
Faculty Sponsor(s): George Sandusky Indiana University-Purdue University Indianapolis
Approximately 55,440 new cases of pancreatic cancer were diagnosed in 2018. Pancreatic ductal adenocarcinoma (PDAC) is the most common type, often involving an epithelial component with a dense fibrous component. There have been no major changes in treatment, or survival rates, in the past 40 years for pancreatic cancer. Stroma influences the tumor microenvironment (TME), and plays a role in the progression of cancer. LOXL2 is a matrix remolding enzyme, which is expressed in the TME. In this study, the expression of LOXL2 in the pancreas was analyzed in six human pancreatic cancer cases, and 30 mice samples from an orthotopic pancreatic cancer mouse model. Each species had two groups, a normal pancreata group and a tumorous pancreata group. The tissues were collected under a patient consented IRB and LARC approved protocol was used for the mouse study. All tissues were fixed, processed, microtomed, and underwent immunostaining by the Dako-Flex system platform. The Aperio digital imaging system was used to scan the slides. The images were analyzed using the Aperio Positive Pixel Algorithm. LOXL2 expression in the normal pancreas in both human and mice were under 2%. In addition, LOXL2 expression seen PDAC was about 30% for mice and 10% for humans. LOXL2 staining was confined to the stroma in the TME in both pancreatic cancer samples. There was no staining observed in the epithelial component of the tumor. In conclusion, LOXL2 is shown to be a positive biomarker to target the TME of pancreatic cancer.
Poster Presentation

When & Where

Irwin Library 3rd Floor